In this direction, molecules acting on the glucagon-like peptide receptor 1 (GLP-1R) have gained particular interest since their administration resulted in consistent BW loss [12], a positive effect on cardiac function [13], and the management of diabetes and metabolic syndrome while also exerting neuroprotective effects [14]. The gene discussed is GLP1R; the disease is metabolic syndrome.